Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Receptor function in heart failure.

M G Bogaert1, N Fraeyman

  • 1Heymans Institute of Pharmacology, University of Gent Medical School, Belgium.

The American Journal of Medicine
|May 29, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Body mass index and occupational accidents among health care workers in a large university hospital.

Acta clinica Belgica·2022
Same author

The drone ambulance [A-UAS]: golden bullet or just a blank?

Resuscitation·2017
Same author

Comparison of the therapeutic effectiveness of aprindine, procainamide and quinidine in chronic ventricular dysrhythmias.

British journal of clinical pharmacology·2012
Same author

Desensitization of muscarinic receptors.

Receptors & channels·2004
Same author

Prefoldin recognition motifs in the nonhomologous proteins of the actin and tubulin families.

The Journal of biological chemistry·2001
Same author

Buflomedil for intermittent claudication.

The Cochrane database of systematic reviews·2001
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric Panniculitis.

The American journal of medicine·2026
Same journal

Hypercalcemia and hyperferritinemia in a patient with Graves' disease disease.

The American journal of medicine·2026
See all related articles

Congestive heart failure involves reduced beta-adrenoceptors due to sympathetic overstimulation. Beta-adrenoceptor blocking agents may counteract this down-regulation, offering potential therapeutic benefits in heart failure patients.

Area of Science:

  • Cardiology
  • Molecular Pharmacology
  • Pharmacology

Background:

  • Congestive heart failure (CHF) is associated with beta-adrenoceptor (β-AR) down-regulation, likely from sympathetic overstimulation.
  • In end-stage dilated cardiomyopathy, β1-AR density is reduced, while β2-AR density is normal, suggesting complex receptor regulation.
  • Other conditions like ischemic cardiomyopathy and mitral valve disease show reduced density of both β1- and β2-ARs.

Purpose of the Study:

  • To investigate the implications of beta-adrenoceptor down-regulation in heart failure.
  • To explore novel therapeutic strategies targeting beta-adrenoceptor pathways in CHF.
  • To evaluate the potential role of beta-adrenoceptor blocking agents in managing heart failure.

Main Methods:

  • Analysis of beta-adrenoceptor density in various heart failure conditions.

Related Experiment Videos

  • Assessment of beta-adrenoceptor/adenylate cyclase complex function.
  • Review of therapeutic approaches including beta-agonists, forskolin, phosphodiesterase inhibitors, and beta-blockers.

    • Main Results:

    • Beta-adrenoceptor down-regulation is a hallmark of congestive heart failure.
    • Beta-agonists may exacerbate down-regulation, limiting their long-term efficacy.
    • Beta-adrenoceptor blocking agents, like metoprolol, might offer benefits by antagonizing this down-regulation.

    Conclusions:

    • Beta-adrenoceptor down-regulation significantly impacts heart failure pathophysiology.
    • Targeting beta-adrenoceptor pathways offers promising therapeutic avenues for CHF.
    • Ongoing studies are crucial to confirm the survival benefits of beta-adrenoceptor blockers in heart failure.